

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
21 August 2025 (21.08.2025)



(10) International Publication Number
WO 2025/174781 A1

(51) International Patent Classification:

A61K 39/00 (2006.01) C07K 16/28 (2006.01)
C07K 14/47 (2006.01)

(21) International Application Number:

PCT/US2025/015439

(22) International Filing Date:

11 February 2025 (11.02.2025)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/552,279 12 February 2024 (12.02.2024) US

(71) Applicant: **JOSLIN DIABETES CENTER** [US/US];
One Joslin Place, Boston, Massachusetts 02215 (US).

(72) Inventors: **LIPES, Myra A.**; c/o Joslin Diabetes Center, One Joslin Place, Boston, Massachusetts 02215 (US).
SOUSA, Giovane R.; c/o Joslin Diabetes Center, One Joslin Place, Boston, Massachusetts 02215 (US).

(74) Agent: **DOHERTY, Elizabeth A.** et al.; MCNEILL PLLC,
245 First Street, 18th Floor, Cambridge, Massachusetts
02142 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: USE OF CARDIAC AUTOANTIBODIES AS A METHOD TO IDENTIFY INDIVIDUALS AT INCREASED RISK OF DEVELOPING CARDIOVASCULAR EVENTS

(57) Abstract: This disclosure relates to cardiac autoantibodies in type 1 diabetes (T1D) and in subjects treated with immune checkpoint inhibitors (ICI) such as cancer subjects, including autoantibodies to myosin heavy chain 6 (MYH6), myosin heavy chain 7 (MYH7), S1-fragment of myosin heavy chain 6, S2-fragment of myosin heavy chain 6, and cardiac troponin I (cTnI). Described herein are uses of these autoantibodies as markers for assessing a person's risk of developing cardiovascular disease.



WO 2025/174781 A1